bioAffinity advances CyPath Lung test for post-treatment lung cancer surveillance
BIAF•CyPath Lung expanded for surveillance use
bioAffinity Technologies advanced a new clinical use for its CyPath Lung test to monitor lung cancer survivors for recurrence or new cancers.
No new study results were presented; the update focused on expanding surveillance use based on prior trials and commercial experience.
The test aims to complement CT scans by helping clinicians judge whether new or changing lung nodules are more likely malignant.
The move targets a large follow-up market, with more than 680,000 Americans living with a prior lung cancer diagnosis as of Jan. 1, 2025.
